Background: Dupuytren’s contracture is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren’s disease. In our this retrospective study the association between phenobarbital and Dupuytren’s contracture is discussed. Case Reports: Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren’s contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren’s disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Conclusions: We believe that phenobarbital causes a dose and time-dipendent profibrotic effect. We notice a clinical regression when phenobarbital was substituted by carbamazepine, maintaining the same dose (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren’s recurrence.

TRIPOLI, M., CORDOVA, A., NAPOLI, N., CHERUBINO, M., MOSCHELLA, F. (2009). Dupuytren's contracture and phenobarbital: our case reports and review of the literature. THE AMERICAN JOURNAL OF CASE REPORTS, 10, 18-21.

Dupuytren's contracture and phenobarbital: our case reports and review of the literature.

CORDOVA, Adriana;MOSCHELLA, Francesco
2009-01-01

Abstract

Background: Dupuytren’s contracture is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren’s disease. In our this retrospective study the association between phenobarbital and Dupuytren’s contracture is discussed. Case Reports: Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren’s contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren’s disease showed different evolutions in relation to dosage and type of antiepileptic drug used. Conclusions: We believe that phenobarbital causes a dose and time-dipendent profibrotic effect. We notice a clinical regression when phenobarbital was substituted by carbamazepine, maintaining the same dose (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren’s recurrence.
2009
Settore MED/19 - Chirurgia Plastica
TRIPOLI, M., CORDOVA, A., NAPOLI, N., CHERUBINO, M., MOSCHELLA, F. (2009). Dupuytren's contracture and phenobarbital: our case reports and review of the literature. THE AMERICAN JOURNAL OF CASE REPORTS, 10, 18-21.
File in questo prodotto:
File Dimensione Formato  
Dupuytren's contracture and phenobarbital.pdf

Solo gestori archvio

Descrizione: articolo principale
Dimensione 302.62 kB
Formato Adobe PDF
302.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/42740
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact